This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Slichenmyer, W. J. Articles by Kastan, M. B. Search for Related Content PubMed PubMed Citation Articles by Slichenmyer, W. J. Articles by Kastan, M. B.

Loss of a p53-associated G1 Checkpoint Does Not Decrease Cell Survival following DNA Damage¹

Departments of Oncology [W. J. S., W. G. N., M. B. K.] and Pathology [R. J. S.], Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

Cell cycle checkpoints regulate progression through the cell cycle. In yeast, loss of the G₂ checkpoint by mutation of the rad9 gene results in increased genetic instability as well as increased sensitivity to ionizing radiation. In contrast, comparing clonogenic survival of cells which are isogeneic except for p53 functional status, we find that loss of a G₁ check-point in mammalian cells is not associated with increased sensitivity to the lethal effects of ionizing radiation or a topoisomerase I inhibitor, camptothecin. These results indicate that increased sensitivity to DNA-damaging agents is not necessarily a defining feature of a mammalian cell cycle checkpoint. Furthermore, in light of a recent link of p53 function to radiation-induced apoptosis in hematopoietic cells, these observations suggest that p53-dependent apoptosis is a cell type-specific phenomenon and thus predict that the biological consequences of loss of p53 function will be cell type specific.

¹ This work was supported by Grant ES05777 from the NIH, Grants 3187 and 3223 from The Council for Tobacco Research, and the Dutch Cancer Society.

² To whom requests for reprints should be addressed.

Received 6/29/93. Accepted 8/ 3/93.

This article has been cited by other articles:

				K. Camphausen and P. J. Tofilon Inhibition of Hsp90: A Multitarget Approach to Radiosensitization Clin. Cancer Res., August 1, 2007; 13(15): 4326 - 4330. [Abstract] [Full Text] [PDF]

				L. de la Pena, W. E. Burgan, D. J. Carter, M. G. Hollingshead, M. Satyamitra, K. Camphausen, and P. J. Tofilon Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol. Cancer Ther., June 1, 2006; 5(6): 1504 - 1510. [Abstract] [Full Text] [PDF]

				X. Wu, S. M. Shell, Z. Yang, and Y. Zou Phosphorylation of Nucleotide Excision Repair Factor Xeroderma Pigmentosum Group A by Ataxia Telangiectasia Mutated and Rad3-Related-Dependent Checkpoint Pathway Promotes Cell Survival in Response to UV Irradiation. Cancer Res., March 15, 2006; 66(6): 2997 - 3005. [Abstract] [Full Text] [PDF]

				N. Kroger, K. Milde-Langosch, S. Riethdorf, C. Schmoor, M. Schumacher, A. R. Zander, and T. Loning Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer Patients Clin. Cancer Res., January 1, 2006; 12(1): 159 - 168. [Abstract] [Full Text] [PDF]

				S. H. Thorne, G. Brooks, Y.-L. Lee, T. Au, L. F. Eng, and T. Reid Effects of Febrile Temperature on Adenoviral Infection and Replication: Implications for Viral Therapy of Cancer J. Virol., January 1, 2005; 79(1): 581 - 591. [Abstract] [Full Text] [PDF]

				E. E. A. Bull, H. Dote, K. J. Brady, W. E. Burgan, D. J. Carter, M. A. Cerra, K. A. Oswald, M. G. Hollingshead, K. Camphausen, and P. J. Tofilon Enhanced Tumor Cell Radiosensitivity and Abrogation of G2 and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin Clin. Cancer Res., December 1, 2004; 10(23): 8077 - 8084. [Abstract] [Full Text] [PDF]

				R. Kitagawa, C. J. Bakkenist, P. J. McKinnon, and M. B. Kastan Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway Genes & Dev., June 15, 2004; 18(12): 1423 - 1438. [Abstract] [Full Text] [PDF]

				S. L. Scott, J. D. Earle, and P. H. Gumerlock Functional p53 Increases Prostate Cancer Cell Survival After Exposure to Fractionated Doses of Ionizing Radiation Cancer Res., November 1, 2003; 63(21): 7190 - 7196. [Abstract] [Full Text] [PDF]

				A. Lasham, S. Moloney, T. Hale, C. Homer, Y. F. Zhang, J. G. Murison, A. W. Braithwaite, and J. Watson The Y-box-binding Protein, YB1, Is a Potential Negative Regulator of the p53 Tumor Suppressor J. Biol. Chem., September 12, 2003; 278(37): 35516 - 35523. [Abstract] [Full Text] [PDF]

				S. J. Edwards, B. R. Dix, C. J. Myers, D. Dobson-Le, L. Huschtscha, M. Hibma, J. Royds, and A. W. Braithwaite Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14ARF Tumor Suppressor Genes J. Virol., November 13, 2002; 76(24): 12483 - 12490. [Abstract] [Full Text] [PDF]

				P. P. McKenzie, C. R. McPake, A. A. Ashford, E. F. Vanin, and L. C. Harris MDM2 Does Not Influence p53-mediated Sensitivity to DNA-damaging Drugs Mol. Cancer Ther., October 1, 2002; 1(12): 1097 - 1104. [Abstract] [Full Text] [PDF]

				Z. Han, W. Wei, S. Dunaway, J. W. Darnowski, P. Calabresi, J. Sedivy, E. A. Hendrickson, K. V. Balan, P. Pantazis, and J. H. Wyche Role of p21 in Apoptosis and Senescence of Human Colon Cancer Cells Treated with Camptothecin J. Biol. Chem., May 3, 2002; 277(19): 17154 - 17160. [Abstract] [Full Text] [PDF]

				B. Xu, S.-T. Kim, D.-S. Lim, and M. B. Kastan Two Molecularly Distinct G2/M Checkpoints Are Induced by Ionizing Irradiation Mol. Cell. Biol., February 15, 2002; 22(4): 1049 - 1059. [Abstract] [Full Text] [PDF]

				I. M. Hussaini, J. E. Carpenter, G. T. Redpath, J. J. Sando, M. E. Shaffrey, and S. R. VandenBerg Protein kinase C-{eta} regulates resistance to UV- and {gamma}-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation Neuro-oncol, January 1, 2002; 4(1): 9 - 21. [Abstract] [PDF]

				N. K. Kim, J. K. Park, K. Y. Lee, W. I. Yang, S. H. Yun, J. Sung, and J. S. Min p53, BCL-2, and Ki-67 Expression According to Tumor Response After Concurrent Chemoradiotherapy for Advanced Rectal Cancer Ann. Surg. Oncol., June 1, 2001; 8(5): 418 - 424. [Abstract] [Full Text] [PDF]

				Y. Nieto, P. J. Cagnoni, S. Nawaz, E. J. Shpall, R. Yerushalmi, B. Cook, P. Russell, J. McDermit, J. Murphy, S. I. Bearman, et al. Evaluation of the Predictive Value of Her-2/neu Overexpression and p53 Mutations in High-Risk Primary Breast Cancer Patients Treated With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation J. Clin. Oncol., May 10, 2000; 18(10): 2070 - 2080. [Abstract] [Full Text] [PDF]

				B. R. Dix, S. J. O’Carroll, C. J. Myers, S. J. Edwards, and A. W. Braithwaite Efficient Induction of Cell Death by Adenoviruses Requires Binding of E1B55k and p53 Cancer Res., May 1, 2000; 60(10): 2666 - 2672. [Abstract] [Full Text]

				K. R. Rogulski, S. O. Freytag, K. Zhang, J. D. Gilbert, D. L. Paielli, J. H. Kim, C. C. Heise, and D. H. Kirn In Vivo Antitumor Activity of ONYX-015 Is Influenced by p53 Status and Is Augmented by Radiotherapy Cancer Res., March 1, 2000; 60(5): 1193 - 1196. [Abstract] [Full Text]

				G. D. Kao, W. G. McKenna, and R. J. Muschel p34Cdc2 Kinase Activity Is Excluded from the Nucleus during the Radiation-induced G2 Arrest in HeLa Cells J. Biol. Chem., December 3, 1999; 274(49): 34779 - 34784. [Abstract] [Full Text] [PDF]

				E. C. Gosink, M. J. Chong, and P. J. McKinnon Ataxia Telangiectasia Mutated Deficiency Affects Astrocyte Growth but not Radiosensitivity Cancer Res., October 1, 1999; 59(20): 5294 - 5298. [Abstract] [Full Text] [PDF]

				J. N. Harada and A. J. Berk p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication J. Virol., July 1, 1999; 73(7): 5333 - 5344. [Abstract] [Full Text]

				J. M. Brown and B. G. Wouters Apoptosis, p53, and Tumor Cell Sensitivity to Anticancer Agents Cancer Res., April 1, 1999; 59(7): 1391 - 1399. [Abstract] [Full Text] [PDF]

				R. G. Syljuasen, B. Krolewski, and J. B. Little Loss of Normal G1 Checkpoint Control Is an Early Step in Carcinogenesis, Independent of p53 Status Cancer Res., March 1, 1999; 59(5): 1008 - 1014. [Abstract] [Full Text] [PDF]

				G. S. Hagopian, G. B. Mills, A. R. Khokhar, R. C. Bast Jr., and Z. H. Siddik Expression of p53 in Cisplatin-resistant Ovarian Cancer Cell Lines: Modulation with the Novel Platinum Analogue (1R, 2R-Diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV) Clin. Cancer Res., March 1, 1999; 5(3): 655 - 663. [Abstract] [Full Text] [PDF]

				M. R. Bennett, T. D. Littlewood, S. M. Schwartz, and P. L. Weissberg Increased Sensitivity of Human Vascular Smooth Muscle Cells From Atherosclerotic Plaques to p53-Mediated Apoptosis Circ. Res., October 19, 1997; 81(4): 591 - 599. [Abstract] [Full Text]

				L. A. Kirshenbaum and D. de Moissac The bcl-2 Gene Product Prevents Programmed Cell Death of Ventricular Myocytes Circulation, September 2, 1997; 96(5): 1580 - 1585. [Abstract] [Full Text]

				N. Nasrin, L. A. Mimish, P. S. Manogaran, M. Kunhi, D. Sigut, S. Al-Sedairy, and M. A. Hannan Cellular Radiosensitivity, Radioresistant DNA Synthesis, and Defect in Radioinduction of p53 in Fibroblasts From Atherosclerosis Patients Arterioscler. Thromb. Vasc. Biol., May 1, 1997; 17(5): 947 - 953. [Abstract] [Full Text]

				N. S. Pellegata, R. J. Antoniono, J. L. Redpath, and E. J. Stanbridge DNA damage and p53-mediated cell cycle arrest: A reevaluation PNAS, December 24, 1996; 93(26): 15209 - 15214. [Abstract] [Full Text] [PDF]

				S. N. Jones, A. T. Sands, A. R. Hancock, H. Vogel, L. A. Donehower, S. P. Linke, G. M. Wahl, and A. Bradley The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2 PNAS, November 26, 1996; 93(24): 14106 - 14111. [Abstract] [Full Text] [PDF]

				R. D. Ennis, J. P.S. Knisely, L. D. Wilson, K. Pantel, H. Gath, E. Heissler, G. D. Kao, M. Rudoltz, S. Denic, J. A. Brennan, et al. Staging of Head and Neck Cancer N. Engl. J. Med., June 29, 1995; 332(26): 1787 - 1790. [Full Text]

				C E Canman, T M Gilmer, S B Coutts, and M B Kastan Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes & Dev., March 1, 1995; 9(5): 600 - 611. [Abstract] [PDF]

				A. S. Lichter and T. S. Lawrence Recent Advances in Radiation Oncology N. Engl. J. Med., February 9, 1995; 332(6): 371 - 379. [Full Text] [PDF]

				L. Hartwell and M. Kastan Cell cycle control and cancer Science, December 16, 1994; 266(5192): 1821 - 1828. [Abstract] [PDF]

				A Di Leonardo, S P Linke, K Clarkin, and G M Wahl DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes & Dev., November 1, 1994; 8(21): 2540 - 2551. [Abstract] [PDF]

				H. P. Rutz, R. O. Mirimanoff, C. Bokemeyer, M. A. Kuczyk, J. Sehrt, M. Muller, M. Volkmann, H. Zentgraf, and P. R. Galle Clinical Implications of the p53 Tumor-Suppressor Gene N. Engl. J. Med., March 24, 1994; 330(12): 864 - 865. [Full Text]

				T A Weinert, G L Kiser, and L H Hartwell Mitotic checkpoint genes in budding yeast and the dependence of mitosis on DNA replication and repair. Genes & Dev., March 15, 1994; 8(6): 652 - 665. [Abstract] [PDF]

				B. Li and M. Y. W. Lee Transcriptional Regulation of the Human DNA Polymerase delta Catalytic Subunit Gene POLD1 by p53 Tumor Suppressor and Sp1 J. Biol. Chem., August 3, 2001; 276(32): 29729 - 29739. [Abstract] [Full Text] [PDF]